| Literature DB >> 28576979 |
Maxmillian Mpina1,2, Nicholas J Maurice3, Masanao Yajima3,4, Chloe K Slichter3,5, Hannah W Miller3, Mukta Dutta3, M Juliana McElrath3,5, Kenneth D Stuart6, Stephen C De Rosa3, John P McNevin3, Peter S Linsley7, Salim Abdulla8, Marcel Tanner1,2, Stephen L Hoffman9, Raphael Gottardo3, Claudia A Daubenberger10,2, Martin Prlic11,5.
Abstract
Animal model studies highlight the role of innate-like lymphocyte populations in the early inflammatory response and subsequent parasite control following Plasmodium infection. IFN-γ production by these lymphocytes likely plays a key role in the early control of the parasite and disease severity. Analyzing human innate-like T cell and NK cell responses following infection with Plasmodium has been challenging because the early stages of infection are clinically silent. To overcome this limitation, we examined blood samples from a controlled human malaria infection (CHMI) study in a Tanzanian cohort, in which volunteers underwent CHMI with a low or high dose of Plasmodium falciparum sporozoites. The CHMI differentially affected NK, NKT (invariant NKT), and mucosal-associated invariant T cell populations in a dose-dependent manner, resulting in an altered composition of this innate-like lymphocyte compartment. Although these innate-like responses are typically thought of as short-lived, we found that changes persisted for months after the infection was cleared, leading to significantly increased frequencies of mucosal-associated invariant T cells 6 mo postinfection. We used single-cell RNA sequencing and TCR αβ-chain usage analysis to define potential mechanisms for this expansion. These single-cell data suggest that this increase was mediated by homeostatic expansion-like mechanisms. Together, these data demonstrate that CHMI leads to previously unappreciated long-lasting alterations in the human innate-like lymphocyte compartment. We discuss the consequences of these changes for recurrent parasite infection and infection-associated pathologies and highlight the importance of considering host immunity and infection history for vaccine design.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28576979 PMCID: PMC5528886 DOI: 10.4049/jimmunol.1601989
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422